Insights from 2023 ESMO Annual Meeting
Playback speed
10 seconds
ESMO 2023 Insights: "A Multicenter, Randomized, Open-Label, Three-Arm, Phase 2/3 GENERATE Study - NabP + Gem vs. Modified FOLFIRINOX or S-IROX in Metastatic or Recurrent Pancreatic Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Akihiro Ohba
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Akihiro Ohba
0 views
October 27, 2023
Comments 0
Login to view comments.
Click here to Login
Gastrointestinal